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ABSTRACT 
At least six different criteria to assume 
attainment of adult height in girls who have 
received growth hormone (GH) treatment have 
been published in the literature. The aim of this 
study was to assess whether, if applied to the 
same population, different criteria for assuming 
adult height would produce the same outcome. 
Methods: Data on Australian and New Zealand 
girls receiving growth hormone (GH) treatment 
were accessed from the nationwide OZGROW 
database. Girls were included in the analysis if 
standing height measurements were available up 
until the time point when bone age (BA) 2:15 yr 
and height velocity (HV) <1 cm/yr (n = 684). 
Participants' height measurements were extrac-
ted from the database at the first time point that 
would be considered to meet the requirements of 
each criterion. 
Results: ANOVA found no statistically signifi-
cant differences between the value for girls' 
adult height assumed when using the various 
criteria. However, as expected, the greatest (and, 
thus, most accurate) estimate for adult height 
was obtained using the most stringent criterion, 
BA >15 yr and HV <1 cm/yr. The values 
assumed using the other adult height criteria 
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underestimated this height value by an average 
of 2.4 cm. 
Conclusion: Statistically similar values for adult 
height in girls who have received GH treatment 
are obtained using any of the published criteria 
for assuming adult height that were evaluated. 
However, in cases where girls who have received 
GH treatment cannot be followed until the time 
point when BA £15 yr and HV cm/yr, it has 
to be acknowledged that the assumed adult 
height is likely to be less than the girl's actual 
adult height. 
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INTRODUCTION 
Throughout the world, thousands of height 
restricted children are treated with growth hormone 
(GH). The main aim of GH treatment in children is 
to improve adult height. As with any medical 
intervention, it is important that children receiving 
GH treatment are regularly monitored, and that 
follow-up occurs to determine whether the treat-
ment regimen implemented has improved their 
final outcome (i.e. adult height). 
Height increases throughout childhood, then 
plateaus at the end of puberty, before eventually 
reaching a static value. Increased height outcome is 
achieved in children receiving GH via promotion of 
the growth of the long bones during childhood and 
early puberty. Adult height is achieved late in 
puberty when, under the influence of sex hormones, 
growth plates fuse and further linear bone growth is 
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prevented. The timing of this event varies between 
girls and boys, and also varies somewhat amongst 
different children of the same gender. 
Given that medical institutions are rarely able 
to follow-up patients receiving GH indefinitely, 
patients' actual adult height often cannot be 
measured. However, knowledge of normal growth 
patterns allows clinicians to estimate the general 
period in development when the majority of linear 
growth will have occurred. Measurement of height 
during this window allows a value for height to be 
obtained that is relatively close to the actual adult 
height. The factors most often used to assume when 
adult height is likely to have occurred are bone age 
(BA) and/or height velocity (HV). The specific 
values of these factors used to assume attainment of 
adult height often vary across different institutions 
and in different studies. 
For example, the Bayley-Pinneau tables1 suggest 
that a girl 's height will have reached 99% of her 
adult height when her BA = 15 years. However, 
many clinicians and researchers are unable to 
follow up patients to this point, and will rely on 
height measurements taken when the patient is less 
mature (i.e. at a lower BA) to approximate adult 
height. In addition, it is important to realise that 
while the Bayley-Pinneau tables can be used to try 
to estimate the percentage of adult height that will 
have been attained at any particular BA, these 
tables are based on data derived from normally 
growing children, and not children with growth 
restrictions (who either have or have not received 
GH treatment), and may not reflect growth patterns 
in this group. As a result, many clinicians and 
researchers use a criterion that incorporates both a 
BA parameter as well as an HV parameter for 
assuming the timing of adult height in girls who 
have received GH treatment. 
On review of the literature, at least six different 
criteria for assuming the timing of adult height in 
girls who have received GH treatment were found 
to be used in various studies2"7. In five of the six 
published criteria, the parameters used to assume 
when adult height occurred included values for 
both BA and HV. The specific values of these 
parameters accepted as approximating the timing of 
adult height differed in the various criteria. 
Currently, it is unknown whether the specific 
criterion used to assume adult height in girls who 
have received GH treatment would alter the actual 
value of this outcome. However, any discrepancies 
in the value of assumed adult height that do occur 
are likely to affect how useful the GH treatment is 
perceived to be. Therefore, the aim of this study 
was to determine whether, if applied to the same 
population, different published criteria for assum-
ing attainment of adult height would produce the 
same adult height values. 
METHODS 
Population 
Data on girls from Australia and New Zealand 
who had received GH treatment as part of a 
government-funded program were accessed from 
the nationwide OZGROW database (n = 3,152). 
Girls were included in the analysis if standing 
height measurements were available up until the 
time point when BA >15 years and HV <1 cm/year. 
In total, data on 684 girls (22%) were available for 
analysis. The remainder of the patients on the 
database were lost to follow-up before this time 
point. All girls in the database had BA determined 
using the Greulich and Pyle method. 
Procedure 
Six different criteria for assuming attainment of 
adult height for girls were extracted from the 
literature (Table 1). Each criterion was applied to 
the data set to determine the value for adult height 
that it would yield. That is, height was evaluated at 
the first time point recorded on the database that 
would be considered to meet the requirements of 
each criterion. In addition, the different BA and HV 
parameters used in the published criteria were also 
individually applied to the data set to determine the 
value for adult height that they would yield. 
Statistical analysis 
Independent-groups ANOVAs were used for 
multiple-group comparisons. Independent-groups 
t-tests were used for two-group comparisons. 
Ρ values <0.05 were considered statistically signifi-
cant. 
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T A B L E 1 
Published criteria for determining attainment of adult height 
1. BA >15 yr and HV <1 cm/yr over 1 year (Pasquino et al., 2000)2 
2. BA >15 yr and HV <1.5 cm/yr over 6 months (Lin-Su et al., 2005)3 
3. BA >15 yr or HV <2 cm/yr over 1 year (Carel et al., 2003)4 
4. BA >14 yr or HV <2 cm/yr over 1 year (Buchlis et al., 1998)5 
5. BA >14 yr and HV <2 cm/yr over 1 year (CGHAC, 2005)6 
6. Last measured height after CA >13.5 yr (Chernausek et al., 2000)7 
B A = bone age; HV = height velocity; CA = chronological age. 
T A B L E 2 
Assumed adult height (cm) when measured using various published criteria, as well as the various 
bone age (BA) and height velocity (HV) parameters (n = 684) 
Criterion/parameter Mean (95% CI) SD SE 
Pasquino et al. (2000)2 151.8 (149.6-154.6) 2.6 0.3 
Lin-Su et al. (2005)3 150.6 (148.5-153.8) 2.8 1.2 
Carel et al. (2003)4 150.4(148.6-151.7) 2.5 0.5 
Buchlis etal. (1998)5 149.8(148.1-149.7) 2.8 0.7 
CGHAC (2005)6 148.7 (146.8-150.3) 3.2 1.1 
Chernausek et al. (2000)7 147.6(144.3-149.1) 3.6 1.8 
BA >15 yr 151.2 (147.8-155.1) 2.1 1.7 
BA >15 yr 150.1 (147.2-152.2) 2.5 1.3 
BA >14 yr 149.1 (146.9-151.8) 3.0 1.1 
BA >14 yr 148.6 (146.8-150.2) 2.9 0.9 
HV <1 cm/yr 150.9(148.8-152.7) 2.8 0.2 
HV <1.5 cm/yr 150.4 (148.7-152.2) 2.4 0.3 
HV <2 cm/yr 149.3 (148.6-150.7) 3.6 0.4 
HV <2 cm/yr 148.2(146.8-150.4) 3.2 0.4 
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RESULTS 
Table 2 lists the height values for girls in the 
O Z G R O W database obtained at the first time point 
that met the requirements of the various published 
criteria for attainment of adult height. ANOVA 
found no statistically significant difference in the 
value of girls' adult height assumed using the 
various published criteria (p = 0.380). A post-hoc 
series of pairwise comparisons found no statisti-
cally significant differences between any of the 
individual criteria. 
Table 2 also lists the height values of girls in the 
O Z G R O W database obtained at the first time point 
recorded on the database that met the requirements 
of the various BA and HV parameters. A N O V A 
found no statistically significant differences between 
the girls' adult height assumed using the various 
BA parameters (p = 0.428) or HV parameters (p = 
0.792). A post-hoc series of pairwise comparisons 
found no statistically significant difference between 
any of the individual BA or HV parameters. 
The highest value for assumed adult height 
(151.8 cm) was obtained using the most stringent 
criterion. BA >15 years and HV <1 cm/year. 
Compared to this value, the adult height assumed 
when using the other published criteria under-
estimated adult height by an average of 2.4 cm. 
Similarly, the adult height value assumed when 
using the various HV and BA criteria under-
estimated this adult height value by an average of 
2.0 and 2.1 cm. respectively (Table 2). 
DISCUSSION 
We found no statistically significant difference 
in the adult height value assumed for girls who had 
received GH treatment using any of the published 
criteria or various BA and HV parameters. How-
ever, as expected, a trend was observed, such that 
the more mature the BA parameter used and/or the 
lower the HV parameter used, the higher the adult 
height value assumed. A mean difference of 2.6 cm 
was found in the girls' height measurements taken 
when BA >14 years compared with when BA >15 
years (Table 2). Similarly, a mean height difference 
of 2.7 cm was found in the girls' measurements 
taken when HV <2 cm/year compared with when 
HV <1 cm/year. 
As expected, the results of this study demon-
strate that the highest (and, therefore, the most 
accurate) estimate for adult height in girls who had 
received GH treatment was obtained when using 
the most stringent criterion, BA >15 year and HV 
<1 cm/year. The other published criteria and the 
various individual HV and BA parameters under-
estimated this adult height value by an average of 
2.0-2.4 cm. Such a difference would be of clinical 
significance. In addition, a difference of this magni-
tude in research findings could alter the perception 
of how useful the GH treatment was in maximising 
adult height. 
CONCLUSION 
Statistically similar values are obtained for adult 
height in girls who have received GH treatment 
using any of the published criteria that were 
evaluated, and for the various BA and HV para-
meters contained within these criteria. However, in 
cases where girls who have received GH treatment 
cannot be followed until the t ime point when BA 
>15 years and HV <1 cm/year, it has to be acknow-
ledged that the assumed adult height is likely to be 
less than the girl 's actual adult height. 
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